Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction in after-hours trading. The company posted revenue of $127.8 million, surpassing the consensus estimate of $110.3 million, while its loss per share of $0.12 was narrower than the anticipated $0.33 loss.

Key Financial Highlights vs. Estimates

• Revenue: $127.8 million (up 64% year-over-year) vs. $110.3 million expected.
• EPS: -$0.12 vs. -$0.33 expected.
• Global net product sales: $127.8 million, driven by strong performance of LIVMARLI ($88.2 million, up 87% YoY) and bile acid medicines ($39.6 million, up 30% YoY).

The company raised its full-year revenue guidance to $490–510 million, reflecting confidence in its commercial execution. Analysts had projected full-year sales of $460.7 million, indicating that Mirum’s updated outlook is significantly more optimistic.

Market Reaction

Following the earnings release, Mirum’s stock rose 8.6% in after-hours trading, suggesting investor approval of the revenue beat, improved profitability, and upward revision in guidance. The stock had been relatively flat in the prior week (+0.04%) and month (-0.1%), indicating that the earnings report was a key catalyst.

Business and Pipeline Updates

• Commercial Performance: LIVMARLI’s U.S. launch of a single oral tablet dose in June contributed to growth, while international sales also showed strength.
• Pipeline Progress:
  • Volixibat (for primary sclerosing cholangitis, PSC) is on track for topline data in Q2 2026.
  • A Phase 2 study for MRM-3379 (Fragile X Syndrome) is expected to begin in Q4 2025.
• Financial Position: Cash reserves increased to $321.7 million, up from $292.8 million at the end of 2024, providing financial flexibility.

Outlook vs. Analyst Estimates

Mirum’s raised revenue guidance of $490–510 million for 2025 is well above the consensus estimate of $460.7 million. For Q3, analysts expect sales of $115.1 million, which the company appears positioned to meet or exceed given current momentum.

For more detailed earnings estimates and historical performance, see Mirum’s earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.